Vasomotor symptom relief versus unwanted effects: role of estrogen dosageBruce Ettinger
Am J Med 118:74-8. 2005
..Furthermore, healthcare providers need to learn how and when to prescribe lower dosages of HT to optimize patient acceptance and continuation...
- When is it appropriate to prescribe postmenopausal hormone therapy?
Bruce Ettinger
University of California, San Francisco, San Francisco, CA, USA
Menopause 13:404-10. 2006
..To develop evidence and consensus-based recommendations for the use of hormone therapy (HT) in postmenopausal women...
- Making the most of managed care dollars spent for postmenopausal osteoporosis
Bruce Ettinger
Department of Medicine, School of Medicine, University of California, San Francisco, USA
Manag Care Interface 18:55-9. 2005
....
- Simple computer model for calculating and reporting 5-year osteoporotic fracture risk in postmenopausal women
Bruce Ettinger
Division of Research, Kaiser Permanente Medical Care Program, Oakland, California, USA
J Womens Health (Larchmt) 14:159-71. 2005
..To devise, validate, and test a software model that improves how clinicians calculate individual risk for osteoporotic fracture and expected treatment benefit...
- Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate
Bruce Ettinger
Division of Research, Kaiser Permanente Medical Care Program, Oakland, California, USA
J Bone Miner Res 19:745-51. 2004
..Conversely, previous alendronate treatment reduced the bone marker and BMD response...
The effects of tibolone in older postmenopausal womenSteven R Cummings
San Francisco Coordinating Center and the California Pacific Medical Center Research Institute, San Francisco, USA
N Engl J Med 359:697-708. 2008
..Tibolone has estrogenic, progestogenic, and androgenic effects. Although tibolone prevents bone loss, its effects on fractures, breast cancer, and cardiovascular disease are uncertain...
- Endogenous estrogen levels and the effects of ultra-low-dose transdermal estradiol therapy on bone turnover and BMD in postmenopausal women
Alison J Huang
Veterans Affairs Medical Center, San Francisco, California, USA
J Bone Miner Res 22:1791-7. 2007
..This suggests that the protective effects of ultra-low-dose estrogen therapy on the postmenopausal skeletal health may depend critically on women's endogenous estrogen levels before treatment...
- Endometrial effects of tibolone in elderly, osteoporotic women
Bruce Ettinger
University of California, San Francisco, San Francisco, California, USA
Obstet Gynecol 112:653-9. 2008
..To investigate endometrial effects of tibolone administered to postmenopausal women for 3 years...
Validation of FRC, a fracture risk assessment tool, in a cohort of older men: the Osteoporotic Fractures in Men (MrOS) StudyBruce Ettinger
Department of Medicine, University of California, San Francisco, CA, USA
J Clin Densitom 15:334-42. 2012
..01) for major osteoporotic fracture. We conclude that the FRC calibrates well with hip and major osteoporotic fractures observed among older men. Further, addition of BMD to the fracture risk calculation improves the tool's performance...
- Use of raloxifene among women with a history of breast cancer
Laurel A Habel
Division of Research, Kaiser Permanente, Oakland, CA 94612, USA
Breast Cancer Res Treat 96:123-9. 2006
..To examine raloxifene use among women with a history of breast cancer...
- Methods for assessing fracture risk prediction models: experience with FRAX in a large integrated health care delivery system
Alice R Pressman
Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA
J Clin Densitom 14:407-15. 2011
..01). Two versions of this risk tool have similar AUROCs, but alternative assessments indicate that addition of BMD improves performance. Multiple methods should be used to evaluate risk tool performance with less reliance on AUROC alone...
- Fracture risk tool validation in an integrated healthcare delivery system
Joan C Lo
Division of Research, Kaiser Permanente Northern California, Oakland, CA 94612, USA
Am J Manag Care 17:188-94. 2011
..To evaluate the utility of the Fracture Risk Calculator (FRC, Foundation for Osteoporosis Research and Education) for predicting 10-year hip fracture risk within a "real world" population...
- Rationale for use of lower estrogen doses for postmenopausal hormone therapy
Bruce Ettinger
156 Lombard Street 13, San Francisco, CA 94111, USA
Maturitas 57:81-4. 2007
....
- Predictors of difficulty when discontinuing postmenopausal hormone therapy
Deborah Grady
Department of Epidemiology and Biostatistics, University of California, San Francisco, USA
Obstet Gynecol 102:1233-9. 2003
..To describe the experiences of postmenopausal women who try to stop hormone therapy and to identify characteristics associated with inability to stop...
- Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial
Bruce Ettinger
Division of Research, Kaiser Permanente Medical Care Program, Oakland, California, USA
Obstet Gynecol 104:443-51. 2004
..5%, 95% confidence interval 0-7.3%). CONCLUSION: Postmenopausal treatment with low-dose, unopposed estradiol increased bone mineral density and decreased markers of bone turnover without causing endometrial hyperplasia...
- High-dose corticosteroid exposure and osteoporosis intervention in adults
Maggie Che
Department of Medicine, Kaiser Permanente Medical Center, Vacaville, California 95688 9430, USA
Ann Allergy Asthma Immunol 97:497-501. 2006
..High-dose corticosteroid exposure is associated with increased risk of bone loss and osteoporotic fractures...
- Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation
Deborah Grady
University of California San Francisco, 1634 Divisadero Street, Suite 600, San Francisco, CA 94115, USA
Obstet Gynecol 104:837-44. 2004
..To examine the effect of raloxifene on major adverse events that occur with postmenopausal estrogen therapy or tamoxifen...
- Early discontinuation of treatment for osteoporosis
Anna N A Tosteson
Department of Medicine, Dartmouth Medical School, Hannover, New Hampshire 03756, USA
Am J Med 115:209-16. 2003
..To identify factors associated with early treatment discontinuation of three agents commonly prescribed for women with low bone density...
- Evolution of postmenopausal hormone therapy between 2002 and 2009
Bruce Ettinger
University of California, San Francisco, CA, USA
Menopause 19:610-5. 2012
..The objective of this analysis was to assess trends in nationwide hormone therapy prescription claims from 2002 to 2009...
- Clinical correlates of atypical femoral fracture
Joan C Lo
Division of Research, Kaiser Permanente Northern California, Oakland, CA 94612, USA
Bone 51:181-4. 2012
..Reports of atypical femur fracture in bisphosphonate-exposed women have prompted interest in characterizing the clinical profiles of these patients...
- Bone mineral density changes during the menopause transition in a multiethnic cohort of women
Joel S Finkelstein
Endocrine Unit, Department of Medicine, Massachusetts General Hospital, 50 Blossom Street, Boston, Massachusetts 02114, USA
J Clin Endocrinol Metab 93:861-8. 2008
..Rates of bone loss across the menopause transition and factors associated with variation in menopausal bone loss are poorly understood...
- Comparison of methods to measure low serum estradiol levels in postmenopausal women
Jennifer S Lee
San Francisco Coordinating Center, California Pacific Medical Center Research Institute, San Francisco, CA 94107, USA
J Clin Endocrinol Metab 91:3791-7. 2006
..Accurate measurement of low serum estradiol (E(2) < 30 pg/ml or < 110 pmol/liter) is needed to study relationships between endogenous E(2) and risks of diseases in older women...
- Effect of the Women's Health Initiative on women's decisions to discontinue postmenopausal hormone therapy
Bruce Ettinger
Division of Research, Kaiser Permanente Northern California, Oakland, Oakland, California 94611 5714, USA
Obstet Gynecol 102:1225-32. 2003
....
- Limb fractures in elderly men as indicators of subsequent fracture risk
Bruce Ettinger
Division of Research, Kaiser Permanente Medical Care Program, Oakland, Calif 94611, USA
Arch Intern Med 163:2741-7. 2003
..Whether limb fracture in elderly men predicts future fracture is unknown...
- A personal perspective on fracture risk assessment tools
Bruce Ettinger
University of California, San Francisco, San Francisco, CA, USA
Menopause 15:1023-6. 2008
..Much more than risk numbers are needed, and, ideally, fracture risk tools should be integrated into bone densitometry reporting or placed into comprehensive, user-friendly, decision aids...
- Tibolone for prevention and treatment of postmenopausal osteoporosis
Bruce Ettinger
156 Lombard Street 13, San Francisco, CA 94111, USA
Maturitas 57:35-8. 2007
..Now that fracture efficacy has been added to the list of tibolone's documented bone benefits, physicians must consider this in the overall risks and benefits of its use...
- Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) Study: a randomized controlled trial
Jeffrey A Tice
Division of General Internal Medicine, Department of Medicine, University of California, San Francisco 94143, USA
JAMA 290:207-14. 2003
..Dietary supplements containing isoflavones are widely used as alternatives to hormonal therapies for hot flashes, but there is a paucity of data supporting their efficacy...
- Measuring symptom relief in studies of vaginal and vulvar atrophy: the most bothersome symptom approach
Bruce Ettinger
University of California, San Francisco, CA, USA
Menopause 15:885-9. 2008
..To assess the importance and usefulness of self-reported symptom data, especially the most bothersome symptom, in the evaluation of treatment for vulvovaginal atrophy...
- Gastric and duodenal safety of daily alendronate
James G Donahue
Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 181 Longwood Ave, Boston, MA 02115, USA
Arch Intern Med 162:936-42. 2002
....
- Effect of isoflavones on lipids and bone turnover markers in menopausal women
Tamara M Knudson Schult
Center for Chronic Disease Outcomes Research, Minneapolis VA Medical Center, MN 55417, USA
Maturitas 48:209-18. 2004
..The purpose of this analysis was to compare the effects of two dietary supplements derived from red clover to placebo on lipids and bone turnover markers in symptomatic menopausal women...
- Hormone predictors of bone mineral density changes during the menopausal transition
MaryFran R Sowers
Department of Epidemiology, School of Public Health, University of Michigan, 339 East Liberty Street, Suite 310, Ann Arbor, MI 48104, USA
J Clin Endocrinol Metab 91:1261-7. 2006
..OBJECTIVE AND CONTEXT: Our objective was to examine predictability of reproductive hormone concentrations for bone mineral density (BMD) loss during the menopausal transition...
- Ethnic variation in bone density in premenopausal and early perimenopausal women: effects of anthropometric and lifestyle factors
Joel S Finkelstein
Endocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA. org
J Clin Endocrinol Metab 87:3057-67. 2002
..Femoral neck BMD is highest in African-Americans and similar in Chinese, Japanese, and Caucasians. These findings may explain why Caucasian women have higher fracture rates than African-Americans and Asians...
- Ethnic variation in bone turnover in pre- and early perimenopausal women: effects of anthropometric and lifestyle factors
Joel S Finkelstein
Endocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA. org
J Clin Endocrinol Metab 87:3051-6. 2002
..Other factors, such as differences in bone accretion, are likely responsible for much of the ethnic variation in adult BMD...
- Appropriate intervention through fracture risk assessment
Bruce Ettinger
Kaiser Permanente Northern California Clinical Professor of Medicine, University of California-San Francisco, USA
Manag Care 14:9-12; discussion 21-3. 2005
- The Classic: Quantitative computed tomography of vertebral spongiosa: a sensitive method for detecting early bone loss after oophorectomy. 1982
Harry K Genant
Clin Orthop Relat Res 443:14-8. 2006
- Uterine and vaginal effects of unopposed ultralow-dose transdermal estradiol
Susan R Johnson
Department of Obstetrics and Gynecology, Roy J and Lucille A Carver College of Medicine, University of Iowa, Iowa City 52242, USA
Obstet Gynecol 105:779-87. 2005
..To investigate uterine effects of unopposed ultralow-dose transdermal estradiol administered to postmenopausal women for 2 years...
- For osteoporosis, are two antiresorptive drugs better than one?
Bruce Ettinger
J Clin Endocrinol Metab 87:983-4. 2002
